Experimental drug opens door for rare sarcoma patients with no options left

NCT ID NCT04225429

NO_LONGER_AVAILABLE Disease control Sponsor: Epizyme, Inc. Source: ClinicalTrials.gov ↗

First seen Jul 02, 2026 · Last updated Jul 02, 2026

Summary

This program provides tazemetostat, an experimental drug taken as a pill twice daily, to adults with advanced epithelioid sarcoma—a rare cancer—who have no satisfactory alternative treatments. It is designed for people who cannot join other clinical studies or access the drug through regular channels. The goal is to offer a potential treatment option for those in serious need.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

tazemetostat

What this could lead to

If it works, this could provide a treatment option for people with advanced epithelioid sarcoma who have run out of alternatives.

What could go wrong

This is an expanded access program, not a formal trial, so results may be limited. The drug may not work for everyone and could cause side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EPITHELIOID SARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

epithelioid sarcoma neoplasm sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EPITHELIOID SARCOMA

More trials for these conditions

Other studies related to the condition(s) this trial covers.